Product Overview
Apalutamide (CAS: 956104-40-8) is a second-generation nonsteroidal androgen receptor (AR) inhibitor with the molecular formula C₂₁H₁₅F₄N₅O₂S (MW: 477.44). It selectively blocks AR signaling, inhibiting tumor growth in prostate cancer by preventing androgen-mediated gene transcription23. This white to off-white crystalline powder is primarily used for treating non-metastatic castration-resistant prostate cancer (NM-CRPC) and metastatic castration-sensitive prostate cancer (mCSPC).
✨ Key Advantages
✅ High Purity: ≥98% (HPLC/GC tested), ensuring pharmaceutical-grade reliability12.
✅ Potent AR Inhibition: Demonstrates IC₅₀ of 16 nM for AR binding, effectively suppressing tumor progression.
✅ Thermal Stability: Stable under recommended storage conditions (2-8°C, dry, and protected from light).
🔬 Application Fields
Oncology: First-line therapy for NM-CRPC and mCSPC, improving survival rates in clinical trials.
Clinical Research: Key compound for studying resistance mechanisms in hormone-sensitive cancers.
Drug Development: Intermediate for synthesizing advanced AR-targeted therapies.
📜 Quality Certifications
Manufactured in GMP-certified facilities, compliant with USP/EP standards.
Rigorous QC via HPLC, NMR, and mass spectrometry for batch consistency.
Complies with MSDS guidelines for safe handling and storage.
📈 Market Insights
The global prostate cancer therapeutics market is projected to reach 20.4B by 2030**‌ (CAGR 8.2%), driven by rising prevalence and demand for targeted therapies. Apalutamide’s role in the ‌**1.5B NM-CRPC treatment segment highlights its commercial relevance.
China
